HeartBeam (BEAT)
Builds cable-free ECG technology that synthesizes a 12-lead reading for arrhythmia assessment.
Something off on this page? Send us feedback.
Develops a portable, cable-free 3D ECG platform that synthesizes a 12-lead ECG for arrhythmia assessment. The company is moving from direct device sales toward licensing its cardiac-signal technology to established partners.
Captures ECG signals in three non-coplanar directions and synthesizes them into a 12-lead ECG. The portable, cable-free platform is intended for clinician-directed assessment outside medical facilities, with FDA clearance limited to arrhythmia assessment.
In 2026, HeartBeam announced a move beyond direct medical-device sales, prioritizing licensing to established partners such as ECG equipment makers, health systems, and wearable companies. Initial commercialization has included a staged rollout planned under a letter of intent with ClearCardio, rather than a completed customer agreement.
Heart-attack detection remains outside the cleared and commercially available indication in the United States.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| Jul 14, 2026 | Maxim Group | Target | $2 | |
| Dec 11, 2025 | H.C. Wainwright | Target | $2.50 | $5.50 |
| Dec 10, 2025 | UBS | Target | $5.50 | |
| Dec 8, 2025 | H.C. Wainwright | Target | $2.50 | |
| Oct 31, 2025 | Roth Capital | Target | $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.7M · Total debt $0 · Total assets $10.6M · Shareholders' equity $8.2M
- Revenue
- $0
- Operating income
- −$5.1M
- Net income
- −$5.0M
No dividends on record.
| Institutions38 holders · as of Mar 31, 2026 | 9.13% | 5.15M shares | |
| Insiders10 holders · as of Aug 13, 2026 | 17.20% | 9.69M shares | |
| Otherremainder | 73.67% | 41.51M shares |
56.35M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Branislav VajdicInsiderdirector, officer: President | 7.05% | 3.97M | Form 4filed Jul 24, 2026 ↗ |
Mark E. StromeInsiderdirector | 6.68% | 3.76M | 13Dfiled Aug 13, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 2.13% | 1.20M | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 1.59% | 898,321 | 13Fas of Mar 31, 2026 |
Willem ElfrinkInsiderdirector | 0.96% | 538,667 | Form 4filed Apr 16, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 16, 2026 | Richard Ferrari | director | +120,000 | $0.8000 |
| Apr 16, 2026 | Mark E. Strome | director | +750,000 | $0.8000 |
| Apr 16, 2026 | Marga Ortigas-Wedekind | director | +25,000 | $0.8000 |
| Apr 16, 2026 | Robert Paul ENO | officer: President | +12,500 | $0.8000 |
| Apr 16, 2026 | Branislav Vajdic | director | +31,250 | $0.8000 |
- GE HealthCare
Ambulatory ECG, Holter, and cardiac-management platform overlap.
- Philips (ADR)
Clinical and ambulatory ECG monitoring from Holter to ePatch.
- iRhythm
Long-term patch ECG monitoring and arrhythmia-analysis service.
- Apple
Consumer wearable ECG and AFib-oriented rhythm notifications.
- Alphabet Class C
Pixel Watch ECG and irregular-heart-rhythm features.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| HeartBeam | $0.4686 | +4.11% | $25.0M | — | — | — | — |
| GE HealthCare | $70.63 | +0.13% | $31.87B | 20.5 | 13.6 | 1.6 | +5.8% |
| Philips (ADR) | $26.22 | −0.62% | $25.77B | 19.6 | 13.5 | 1.3 | −2.9% |
| iRhythm | $121.95 | −0.55% | $4.03B | — | 245.7 | 4.9 | +20.1% |
| Apple | $324.52 | −0.14% | $4.77T | 37.2 | 35.3 | 10.2 | +16.4% |
| Alphabet Class C | $334.92 | +0.33% | $4.05T | 16.8 | 24.9 | 9.2 | +24.2% |
| Median | 20.0 | 24.9 | 4.9 | +16.4% |